Instituto Universitario de Oftalmobiología Aplicada   Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4
Founded: Valladolid Spain (2009)

Organization Overview

First Clinical Trial
2009
NCT00309192
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

Active Ingredients

Drugs in Phase 4 Trials (1)

cyclosporine (sandimmune) (1 trial)

Drugs in Phase 3 Trials (4)

bevacizumab (avastin) (3 trials)

fluorometholone (fml) (1 trial)

triamcinolone (kenalog) (1 trial)

verteporfin (visudyne) (1 trial)

Drugs in Phase 1 Trials (1)

bosentan (tracleer) (1 trial)

Drugs in Other Trials (3)

crocin (1 trial)

hyaluronic acid (1 trial)

monophosphoryl lipid a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 3)

Dry Eye Syndromes (Phase 4)

Edema (Phase 3)

Eye Diseases (Phase 3)

Keratitis (Phase 4)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 4)

Macular Edema (Phase 3)

Myopia (Phase 3)

Neovascularization, Pathologic (Phase 3)

Retinal Vein Occlusion (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9